A Prescription Drug User Fee Act target date has been set for the fourth quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza ...

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Roche (RHHBY) said on Thursday that the U.S. Food and Drug Administration has accepted its supplemental biologics license application seeking approval for Tecentriq and Tecentriq Hybreza, in ...

Cemdisiran achieved significant, placebo-adjusted functional improvements as both monotherapy and combination therapy in patients with gMG. The Food and Drug Administration (FDA) has accepted for ...

Metro journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission – learn more Football fans rejoice; the 2026 FIFA World ...

Add Yahoo as a preferred source to see more of our stories on Google. The submission is supported by data from the Phase III ATOMIC study. Credit: Gorodenkoff / Shutterstock.com. (Gorodenkoff / ...

As England and Scotland football fans start to enjoy a string of late-night World Cup kick-offs, O2 is offering customers thousands of free caffeine pickmeups at Greggs the morning after every game.

Roughly an hour earlier, the 25-year-old had walked out to the sort of wild reaction that greeted John McGinn hitting the back of the net against Haiti, with screams and hollers from the teenagers ...

(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has accepted and granted priority review to a supplemental biologics licence application for Ultomiris as a treatment ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, ...